<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095522</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-13-YA-0636-CTIL</org_study_id>
    <nct_id>NCT02095522</nct_id>
  </id_info>
  <brief_title>COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients</brief_title>
  <acronym>CODEN</acronym>
  <official_title>Does COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients?: A Prospective Randomized, Double-blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colchicine has antiinflammatory properties. It has been shown to be effective in improving&#xD;
      outcome in stable coronary disease. The exact mechanism is unclear. Study objective: to&#xD;
      assess the effect of colchicine on endothelial function using the EndoPAT™ in NSTEMI&#xD;
      Patients.&#xD;
&#xD;
      Study Hypothesis: There will be a significant difference on the RH-PAT levels of the patients&#xD;
      who were in treated with colchicine versus the placebo group Study design and patient&#xD;
      Selection One hundred and forty patients with the diagnosis of Non ST Elevation Myocardial&#xD;
      Infarction will be enrolled to a prospective randomized double-blind placebo controlled study&#xD;
      in Tel Aviv Medical Center, Tel Aviv, Israel. Patients will be recruited during their&#xD;
      hospitalization before cardiac catheterization. All patients will sign an informed consent.&#xD;
&#xD;
      Primary outcome will be the improvement in endothelial function between baseline and after 1&#xD;
      month in both groups&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and patient Selection One hundred and forty patients with the diagnosis of Non&#xD;
      ST Elevation Myocardial Infarction (NSTEMI) will be enrolled to a prospective randomized&#xD;
      double-blind placebo controlled study in Tel Aviv Medical Center, Tel Aviv, Israel. Patients&#xD;
      will be recruited during their hospitalization before cardiac catheterization. All patients&#xD;
      will sign an inform consent. Study will be published on NIH clinicaltrials.com database.&#xD;
&#xD;
      Inclusion and exclusion criteria are presented in Table 1 Table 1: Patient Selection&#xD;
      Inclusion criteria&#xD;
&#xD;
      1. NSTEMI Diagnosis 2. Patients above the age of 18 3. Informed consent Exclusion criteria&#xD;
&#xD;
        1. Hemodynamic instability&#xD;
&#xD;
        2. Pregnant women&#xD;
&#xD;
        3. Peripheral vascular disease with feeble or absent peripheral pulses&#xD;
&#xD;
        4. Restlessness and/or chaotic breathing&#xD;
&#xD;
        5. Renal dialysis&#xD;
&#xD;
        6. Severe aortic valve insufficiency/Stenosis&#xD;
&#xD;
        7. Severe mitral valve insufficiency&#xD;
&#xD;
        8. Congenital cardiac malformations (structural heart diseases)&#xD;
&#xD;
        9. Known extra-cardiac shunts&#xD;
&#xD;
       10. Major surgery within 30 days&#xD;
&#xD;
       11. Any medical condition that would impair participation (e.g. progressive neurological&#xD;
           disorders, mental illness)&#xD;
&#xD;
       12. Known intolerance to colchicine&#xD;
&#xD;
       13. Ejection fraction less than 35% or past admission for CHF exacerbation in the last 30&#xD;
           days.&#xD;
&#xD;
       14. Inflammatory diseases&#xD;
&#xD;
       15. Current treatment with steroids, NSAID, chemotherapy or biologic medications&#xD;
&#xD;
      Pre Study exam&#xD;
&#xD;
      After enrollment, patients will undergo the following baseline procedure:&#xD;
&#xD;
        1. Physical examination and medical interview&#xD;
&#xD;
        2. Endothelial function using the EndoPat® before planned cardiac catheterization&#xD;
&#xD;
        3. Blood tests- see below for description&#xD;
&#xD;
      Blood sampling An 18-gauge cannula will be placed in an antecubital vein for blood sampling.&#xD;
      Blood sample analyses will be performed using reagents, calibrators and control materials&#xD;
      from Bayer Diagnostics (Berkshire, England) on the ADVIA 1650. A 40 ml blood sample will be&#xD;
      obtained as described below. Blood tests timing is detailed at the end in the flow chart.&#xD;
&#xD;
      Each Patient will provide 40ml of blood for the following blood tests&#xD;
&#xD;
        1. Full chemistry including: lipid levels, thyroid function, liver enzymes function,&#xD;
           Troponin, CPK, HbA1c, uric acid, and glucose levels.&#xD;
&#xD;
        2. Blood count&#xD;
&#xD;
        3. Inflammatory biomarker (hs-CRP, fibrinogen, IL-6, IL-1B, IL-18, MMP, Lp-PLA2,&#xD;
           procalcitonin, IL-10, IL-35, TNFa, AchE, , PAI-1, MPO, cholinergic status. etc.)&#xD;
&#xD;
        4. Endothelial function markers: Endothelin-1, I-CAM, V-CAM, superoxide dismutase ADMA, and&#xD;
           oxidized LDL&#xD;
&#xD;
        5. Serum Samples will be stored for future testing.&#xD;
&#xD;
      PAT score:&#xD;
&#xD;
      Peripheral arterial tonometry signals will be obtained using the EndoPAT 2000 device (Itamar&#xD;
      Medical Inc., Caesarea, Israel), which has been validated and used previously to assess&#xD;
      peripheral arterial tone in other populations. 14-17 Briefly, EndoPAT bio-sensors are placed&#xD;
      on the index fingers of both arms. EndoPAT quantifies the endothelium-mediated changes in&#xD;
      vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard&#xD;
      blood pressure cuff). When the cuff is released, the surge of blood flow causes an&#xD;
      endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as reactive&#xD;
      hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A&#xD;
      post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the&#xD;
      EndoPAT index. In addition, the EndoPAT system will measure heart rate variability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The investigators did not find suiable patients&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of RH-PAT at 1 month (a marker of endothelial function)</measure>
    <time_frame>1 month</time_frame>
    <description>RH-PAT will be measured before the angiography and after one month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in inflammatory biomarkers (before cardiac catheterization, after cardiac catheterization and at 1 month time follow-up)</measure>
    <time_frame>1 month</time_frame>
    <description>biomarkers will be assessed before and after the angiography. Comparison of the biomarker levels will be assessed between the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in endothelial function markers.</measure>
    <time_frame>1 month</time_frame>
    <description>serum ICAM VACAM and endothelin will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory biomarkers Improvement of heart rate variability (HRV)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cholinergic status</measure>
    <time_frame>1 month</time_frame>
    <description>serum ACHE will be measured at randomization and after one month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Acute Kidney Injury post PCI</measure>
    <time_frame>1 month</time_frame>
    <description>AKI will be defined per AKIN as an increase of 0.3mg/dl. The two treatment groups will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in radial artery occlusion</measure>
    <time_frame>acute</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of peri-procedural myocardial infarction</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse clinical events (MACE) defined as a composite of all-cause mortality, myocardial infarction, repeat revascularization, and 30 day readmission rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life under colchicine treatment</measure>
    <time_frame>1 month</time_frame>
    <description>The investigators will assess this outcome using a standard quality of life questionnaire (EQ5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Safety will be assessed by comparing adverse events between the two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>NSTEMI</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 1mg per day for one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 1mg per day for one month</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet 1mg per day for a month</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. NSTEMI Diagnosis&#xD;
&#xD;
          2. Patients above the age of 18&#xD;
&#xD;
          3. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemodynamic instability&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Peripheral vascular disease with feeble or absent peripheral pulses&#xD;
&#xD;
          4. Restlessness and/or chaotic breathing&#xD;
&#xD;
          5. Renal dialysis&#xD;
&#xD;
          6. Severe aortic valve insufficiency/Stenosis&#xD;
&#xD;
          7. Severe mitral valve insufficiency&#xD;
&#xD;
          8. Congenital cardiac malformations (structural heart diseases)&#xD;
&#xD;
          9. Known extra-cardiac shunts&#xD;
&#xD;
         10. Major surgery within 30 days&#xD;
&#xD;
         11. Any medical condition that would impair participation (e.g. progressive neurological&#xD;
             disorders, mental illness)&#xD;
&#xD;
         12. Known intolerance to colchicine&#xD;
&#xD;
         13. Ejection fraction less than 35% or past admission for CHF exacerbation in the last 30&#xD;
             days.&#xD;
&#xD;
         14. Inflammatory diseases&#xD;
&#xD;
         15. Current treatment with steroids, NSAID, chemotherapy or biologic medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Arbel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64329</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky medical center (Ichilov)</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Tel-Aviv Medical Center</investigator_title>
  </responsible_party>
  <keyword>colchicine NSTEMI endothelial function inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

